Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NeuroPace (NPCE) Research & Development (2020 - 2026)

NeuroPace has reported Research & Development over the past 7 years, most recently at $7.2 million for Q1 2026.

  • For Q1 2026, Research & Development fell 3.37% year-over-year to $7.2 million; the TTM value through Mar 2026 reached $27.6 million, up 9.2%, while the annual FY2025 figure was $27.9 million, 17.9% up from the prior year.
  • Research & Development for Q1 2026 was $7.2 million at NeuroPace, up from $7.0 million in the prior quarter.
  • Over five years, Research & Development peaked at $7.4 million in Q1 2025 and troughed at $4.8 million in Q3 2023.
  • A 5-year average of $6.0 million and a median of $5.8 million in 2024 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: surged 36.02% in 2022 and later fell 14.54% in 2023.
  • Year by year, Research & Development stood at $5.1 million in 2022, then rose by 5.66% to $5.4 million in 2023, then grew by 12.52% to $6.0 million in 2024, then rose by 16.15% to $7.0 million in 2025, then grew by 2.31% to $7.2 million in 2026.
  • Business Quant data shows Research & Development for NPCE at $7.2 million in Q1 2026, $7.0 million in Q4 2025, and $6.6 million in Q3 2025.